CAR T Therapy Is Becoming More Decentralized and Patient Centered – City of Hope
City of Hope shared a post on LinkedIn:
“The delivery of cell therapies is evolving faster than many realize.
CAR T and other cellular treatments are expected to become more decentralized in 2026, with care shifting into outpatient clinics and select home-based settings.
This transition, supported by remote monitoring and digital health, has the potential to significantly reduce hospital stays, lower overall costs and expand access to complex cancer therapies.
Eileen Smith, M.D., the Francis and Kathleen McNamara Distinguished Chair and Professor, Department of Hematology and Hematopoietic Cell Transplantation, outlines how City of Hope‘s model, developing cell therapies on site and delivering care beyond inpatient settings, is helping set a new national standard for patient-centered treatment.”
Proceed to the video attached to the post.
Stay updated with Hemostasis Today.
-
Aug 31, 2026, 14:32Mahir Khalil Ibrahim Jallo: Hot Topic From The ESC 2026 Munich
-
Aug 31, 2026, 14:28Ruben Mesa: FDA Approves Ropeginterferon Alfa-2b for Essential Thrombocythemia
-
Aug 31, 2026, 14:28Francisco Chacón-Lozsán: Should We Anticoagulate AF Patients With Only One Non-Sex Stroke Risk Factor?
-
Aug 31, 2026, 14:24Akl Fahed: Do Lifelong Differences in LDL Cholesterol Influence the Risk of Venous Thromboembolism?
-
Aug 31, 2026, 14:23Accelerating CAR-T Access Through Policy and System Reform – American Society of Hematology
-
Aug 31, 2026, 14:21Shirya Rashid: Does Bempedoic Acid Influence Venous Thromboembolism Risk?
-
Aug 31, 2026, 14:14Jason Andrade: SINGLE-AF Trial Validates Early Anticoagulation in AF
-
Aug 31, 2026, 14:12Leonardo Roever: Diagnosis and Management of Natural Anticoagulant Deficiencies
-
Aug 31, 2026, 14:07Ben Dowsing: Can Heart Failure Therapy Be Safely Withdrawn After HER2 Cardiotoxicity Recovery